Roche Holding AG's diagnostics division and U.S.-based Mayo Clinic have agreed to investigate offering drug selection and dosing information for the treatment of psychiatric patients.Technorati Tags: Roche, Mayo Clinic, AmpliChip, CYP450
The companies' first step is to co-develop a prototype IT-enabled system that will refine Mayo Clinic's extensive psychiatric and pharmacogenomic clinical expertise, Roche said in a statement on Tuesday.
The prototype system will offer drug selection and dosing information for a broad range of psychotropic therapeutics based on patient test results from Roche's AmpliChip CYP450 test.
Tuesday, October 11, 2005
A previous posting on the AmpliChip CYP450 test for individual variability in drug metabolism (one of Forbes' "top ten medical tests you need," oddly) is here. Via Reuters: